Summary of the pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.
User avatar
dignan
Family Elder
Posts: 1612
Joined: Wed Aug 11, 2004 2:00 pm

Post by dignan »

I finally moved daclizumab from phase 2 to phase 3 based on the post from Frank a few days ago. It's still in a phase 2 trial, but I figured I just move it into phase 3.
User avatar
lmacalus
Family Member
Posts: 66
Joined: Sun Apr 05, 2009 2:00 pm
Contact:

HALT MS

Post by lmacalus »

Is there anything else you can share on this study - I am being considered as a canidate as I type and am cautiously optomistic!
User avatar
dignan
Family Elder
Posts: 1612
Joined: Wed Aug 11, 2004 2:00 pm

Post by dignan »

Sorry, I don't really know any more. All I've seen are the news articles, based on this press release:

http://investors.facetbiotech.com/phoen ... highlight=
User avatar
dignan
Family Elder
Posts: 1612
Joined: Wed Aug 11, 2004 2:00 pm

Post by dignan »

I moved PI-2301 from phase 1 to phase 2, based on THIS post from scorpion.
User avatar
dignan
Family Elder
Posts: 1612
Joined: Wed Aug 11, 2004 2:00 pm

Post by dignan »

I updated the list (and the progressive list) based on scorpion's post:
http://www.thisisms.com/ftopict-8150.html
User avatar
dignan
Family Elder
Posts: 1612
Joined: Wed Aug 11, 2004 2:00 pm

Post by dignan »

I removed Atacicept (aka TACI-Ig) (Merck Serono and ZymoGenetics) from the phase 2 list based on this post from scorpion:
http://www.thisisms.com/ftopicp-69164.html#69164
User avatar
dignan
Family Elder
Posts: 1612
Joined: Wed Aug 11, 2004 2:00 pm

Post by dignan »

I moved "R3477 (aka ACT-128800) (Roche / Actelion)" from phase 1 to phase 2, based on this post from scorpion:
http://www.thisisms.com/ftopicp-70568.html#70568
User avatar
dignan
Family Elder
Posts: 1612
Joined: Wed Aug 11, 2004 2:00 pm

Post by dignan »

I removed BCX-4208 from the phase 1 list because there is no indication that they are testing on MS patients right now and it is being tested on people with gout, which suggests to me it won’t be helpful in MS, since low uric acid is seen in some MS patients, whereas gout is a problem with high uric acid levels.

http://investor.shareholder.com/biocrys ... eID=332229

http://tinyurl.com/y9vb8d3
User avatar
dignan
Family Elder
Posts: 1612
Joined: Wed Aug 11, 2004 2:00 pm

Post by dignan »

I moved BGC20-0134 (BTG) from phase 1 to phase 2, based on the page on BTG's website:
http://www.btgplc.com/BTGPipeline/233/BGC200134.html

It's a good day.
User avatar
dignan
Family Elder
Posts: 1612
Joined: Wed Aug 11, 2004 2:00 pm

Post by dignan »

I just took a hatchet to the phase 1 list. If anybody wants the gory details, they are here: http://mspipeline.wordpress.com/category/updates/
User avatar
dignan
Family Elder
Posts: 1612
Joined: Wed Aug 11, 2004 2:00 pm

Post by dignan »

I added AIN457 (Novartis) to the phase 2 list based on this clinicaltrials.gov entry:

http://www.clinicaltrials.gov/ct2/show/NCT01051817
User avatar
dignan
Family Elder
Posts: 1612
Joined: Wed Aug 11, 2004 2:00 pm

Post by dignan »

I added BIIB033 (Anti-Lingo) to the phase 1 list based on a post from ElMarino. The post cites a Dow Jones article. The trial is also now listed in clinicaltrials.gov

http://english.capital.gr/news.asp?id=896271

http://www.clinicaltrials.gov/ct2/show/NCT01052506
User avatar
rainer
Family Elder
Posts: 367
Joined: Thu Jan 17, 2008 3:00 pm

Post by rainer »

dignan wrote:Another one for pre-clinical - LLDT-8. The thing I'm happy to see here is that this research comes from China. I'd love to see the MS research world harness some more of the immense brain-power in China and India.



(5R)-5-Hydroxytriptolide (LLDT-8 ), a novel triptolide derivative, prevents experimental autoimmune encephalomyelitis via inhibiting T cell activation.

J Neuroimmunol. 2006 May 17; [Epub ahead of print]
Fu YF, Zhu YN, Ni J, Zhong XG, Tang W, Zhou R, Zhou Y, Dong JR, He PL, Wan H, Li YC, Yang YF, Zuo JP.
Laboratories of Immunopharmacology and Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China.

A novel triptolide derivative (5R)-5-hydroxytriptolide (LLDT-8 ) has been shown to have potent immunosuppressive activities. Here LLDT-8 was evaluated in experimental autoimmune encephalomyelitis (EAE), the model of multiple sclerosis (MS).

LLDT-8 reduced the incidence and severity of EAE, which was associated with the inhibition of the MOG 35-55 lymphocyte recall response, anti-MOG 35-55 T cell responses, interleukin (IL)-2 and interferon (IFN)-gamma production. In vitro, LLDT-8 inhibited primary T cells proliferation, division, IL-2 and IFN-gamma production stimulated with anti-CD3/28.

These findings highlight the fact that LLDT-8 prevents EAE by suppressing T cell proliferation and activation, with a potential for treatment of MS.

<shortened url>
Man, I really wish someone would pursue the Triptolide angle. A naturally occurring compound that targets the ever mentioned IL-2. I'd be tempted to order it from China but it is highly toxic as evidenced by its comically horrifying nicknames: "Walk Seven Steps and Die Vine" and "Intestine Breaking Plant" 8O
User avatar
dignan
Family Elder
Posts: 1612
Joined: Wed Aug 11, 2004 2:00 pm

Post by dignan »

Rainer, yeah, I don't like the sounds of those nicknames. I'm happy to wait for some pharmaceutical derivative that would be safer. Maybe, "walk seven steps and stop for a little rest".
User avatar
harpgirl
Family Member
Posts: 57
Joined: Mon Jul 05, 2010 2:00 pm
Contact:

Post by harpgirl »

Just read it all, and to everyone, AWSOME, just Awsome!
-<em> Cindy (aka Harpgirl)</em><br />
Post Reply

Return to “Drug Pipeline”